心不全管理のための新しいウェアラブル デバイス
心不全の非侵襲的管理における特許取得済みのセンシング技術に基づく新しいウェアラブル デバイスの臨床トランスレーショナル リサーチ
Heart failure (HF) is a major cardiovascular disease with high readmission and mortality rate. A wearable device that could remotely monitor and detect the worsening HF early before the symptoms appear will help reduce HF readmissions effectively. The purpose of the current study is to examine the efficiency of a novel wearable device based on flexible strain sensor comparing to the clinical 'gold standard,' and then transform it into a clinical application.
調査の概要
詳細な説明
The prospective cohort study aims to examine the efficiency of a novel wearable device based on a flexible strain sensor to improve the outcomes of patients with HF compared to the standard-of-care without wearable device monitoring.
The primary and secondary endpoints will be examined in subgroups determined by baseline variables reflecting demography,NYHA functional class,left ventricular ejection fraction,natriuretic peptide,additional co-morbidities,and others.
研究の種類
入学 (推定)
段階
- 適用できない
連絡先と場所
研究連絡先
- 名前:Di Sun, Dr.
- 電話番号:010-84206809
- メール:sundi0929@163.com
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Diagnosis of HF ≥ 3 months
- Diagnosis of NYHA Class III HF
- Subjects with age ≥ 18 years
- At least 1 HF hospitalization within 12 months prior to enrollment
- Subjects with elevated ambulatory levels of BNP/NT-proBNP
Exclusion Criteria:
- Subjects unable to cooperate to complete the trial.
- Subjects with severe arrhythmia.
- Subjects with cardiac shock.
- Subjects with acute myocardial infarction.
- Subjects with local skin infections and injuries in the jugular vein area
- Subjects with active uncontrolled infections
- Subjects with eGFR < 25 mL/min/1.73m2
- Pregnant women, or women likely to undergo pregnancy
- Subjects with life expectancy less than 6 months
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:ふるい分け
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Novel wearable device strategy group
Patients with a novel wearable device for monitoring and uploading data daily to collect monitoring data such as jugular vein pressure and exercise steps. |
Patients with a novel wearable device for monitoring and uploading data daily to collect monitoring data such as jugular vein pressure and exercise steps after discharge. |
|
介入なし:Control group
Patients receive a standard of care for heart failure without a wearable device. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Rate of Hospital Readmissions for Heart Failure
時間枠:Up to 6 months
|
Total hospitalizations for heart failure will be monitored via follow-up. |
Up to 6 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Concordance of the Jugular Vein Pressure with the RHC Measurement
時間枠:Up to 6 months
|
Accuracy of jugular vein pressure measurements by the novel wearable device compared to right heart catheterization. |
Up to 6 months
|
|
Change From Baseline N-terminal Pro-brain Natriuretic Peptide(NT-proBNP) or Brain Natriuretic Peptide(BNP)
時間枠:Up to 6 months
|
Change from baseline to 6 months in N-terminal pro-brain natriuretic peptide (NT-proBNP) or Brain Natriuretic Peptide(BNP). NT-proBNP/BNP level will be measured using commercial kits system during the follow-up period. Change from baseline was defined as the value of NT-proBNP/BNP at 6 months minus the baseline value. Baseline value was defined as the mean of all available measurements from the screening visit. |
Up to 6 months
|
|
Change in Exercise Capacity as Measured by the 6-Minutes-Walking-Test (6MWT) Distance.
時間枠:Up to 6 months
|
Change from baseline to 6 months in exercise capacity as measured by the distance walked in 6 minutes in standardised conditions. |
Up to 6 months
|
|
Compliance Percentage of Patients
時間枠:Up to 6 months
|
Patient adherence to daily measurement and transmission of sensor readings will be recorded. |
Up to 6 months
|
|
Change in Quality of Life
時間枠:Up to 6 months
|
Quality of life will be measured with the Kansas City Cardiomyopathy Questionnaire (KCCQ) answered by the patients directly on a patient application.KCCQ is a 23-item, self-administered instrument that quantifies physical function, symptoms (frequency, severity and recent change), social function, self-efficacy and knowledge, and quality of life. The KCCQ total symptom score incorporates the symptom domains into a single score. Scores are transformed to a range of 0-100, in which higher scores reflect better health status. |
Up to 6 months
|
|
Change in New York Heart Association (NYHA) functional class.
時間枠:Up to 6 months
|
NYHA class will be evaluated according to the patients' clinical characteristics during the follow-up.NYHA Functional Classification places patients in one of four categories based on how much they are limited during physical activity; Class I being best and Class IV being the worst functional class. Class I has no limitation to physical activity, Class II has slight limitation to physical activity, Class III has marked limitation of physical activity, and Class IV is unable to carry out any physical activity without severe discomfort. |
Up to 6 months
|
|
Freedom From a Device/System-related Complication
時間枠:Up to 6 months
|
Device/System-related Complications refer to adverse events such as device failure and allergy. |
Up to 6 months
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Subjects Included the Endpoint of Cardiovascular Mortality
時間枠:Up to 6 months
|
Rate of cardiovascular mortality will be monitored via follow-up. |
Up to 6 months
|
|
Subjects Included the Endpoint of all-cause Mortality
時間枠:Up to 6 months
|
Rate of all-cause mortality will be monitored via follow-up. |
Up to 6 months
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。